NCT02701153
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
Recruiting
NAAges 18+InterventionalTreatmentJonsson Comprehensive Cancer CenterInvestigator-initiated
~51 participants
Updated 2026-03-10 on ClinicalTrials.gov
What's tested:Conventional SurgeryHypofractionated Radiation TherapyLaboratory Biomarker AnalysisQuestionnaire Administration
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Grade >= 2 radiation morbidity (subcutaneous tissue fibrosis, joint stiffness, or edema)
Measured over Up to 2 years
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Study leadership
- Anusa Kalbasi, MD · PRINCIPAL_INVESTIGATOR · UCLA / Jonsson Comprehensive Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Histologically confirmed soft tissue sarcoma of the extremity/trunk
Intermediate or high grade sarcoma
Resectable primary lesion (patients with pre-existing metastasis will be included if their primary is still going to be resected)
Recurrent, any grade, no previous radiation therapy
Karnofsky performance status (KPS) \>= 70 or Eastern Cooperative Oncology Group (ECOG) 0 - 2
If a woman is of childbearing potential, a negative serum pregnancy test must be documented
Exclusion
Active treatment of a separate malignancy
History of prior irradiation to the area to be treated
Pre-operative chemotherapy (post-op acceptable)
What this trial measures
- Grade >= 2 radiation morbidity (subcutaneous tissue fibrosis, joint stiffness, or edema)Up to 2 years
Interim reports will be prepared every six months until the results of the study are published. In general, the interim reports will contain information about patient accrual rate with projected completion dates, status of question-answer (QA) review and compliance rate of treatment per protocol, and the frequencies and severity of toxicity.